吡柔比星与羟基喜树碱膀胱灌注预防表浅性膀胱癌术后复发的疗效对比

Therapeutic comparison of bladder instillation with hydroxycamptothecine and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer

目的：对比分析吡柔比星（ THP）与羟基喜树碱（ HCPT）膀胱灌注预防表浅性膀胱癌术后复发的效果。方法选择2010年12月—2011年12月蚌埠医学院第一附属医院收治的80例表浅性膀胱癌术后患者,按数字表法随机分为两组,各40例,分别采用THP （ THP组）和HCPT（ HCPT组）予以膀胱灌注治疗。观察并比较两组治疗后3、6、12、24个月膀胱癌的复发情况以及不良反应发生情况。结果所有患者均随访24个月。 THP组复发率15．0%（6/40）,HCPT组复发率17．5%（7/40）,差异无统计学意义（χ2=0．092, P〉0．05）。 THP组不良反应发生率27．5%（11/40）,HCPT组不良反应发生率17．5%（7/40）,两组差异无统计学意义（χ2=1．147, P〉0．05）。结论 THP与HCPT膀胱灌注用于预防表浅性膀胱癌术后复发的疗效相似且不良反应较轻,耐受性好,均可作为一线药物用于临床膀胱灌注治疗。

Objective To evaluate the effects of bladder instillation with hydroxycamptothecine and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer. Methods From December 2010 to December 2011, 80 patients of postoperative superficial bladder cancer were selected in the First Affiliated Hospital of Bengbu Medical College. According to random number table, to patients were divided into two groups：pirarubicin group（40） and hydroxycamptothecine group（40）, different drugs were used, the occurrence and adverse reactions at 3, 6, 12, 24 months after treatment were closely observed. Results All patients were followed up for 24 months, the recurrence rate of hydroxycamptothecine and pirarubicin group were 15. 0%（6/40） and 17. 5%（7/40）, the diference was not statistically significant（χ2=0. 092, P〉0. 05）. The incidence rate of adverse reactions in hydroxycamptothecine and pirarubicin group were 27. 5%（11/40） and 17. 5%（7/40）, the difference was not statistically significant（χ2 =1. 147, P〉0. 05）. Conclusions The effects of bladder instillation with hydroxycamptothecine and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer are similar. These two drugs can be used as the promising drug for bladder instillation.